Dr. Michael Milsom gained his PhD in Biochemistry and Molecular Biology from the University of Leeds in the UK. For his first postdoctoral position, he joined the group of Dr. Leslie Fairbairn at the Paterson Institute for Cancer Research in Manchester, in order to study gene therapy of hematopoietic stem cells. He then moved to the USA to undertake a second postdoctoral fellowship in the group of Dr. David A. Williams at Cincinnati Children’s Hospital Medical Center. He next took up a junior faculty position at Harvard Medical School/Children’s Hospital Boston within the Division of Hematology/Oncology, again under the mentorship of Dr. Williams.
He joined the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH) by the German Cancer Research Center (DKFZ) as a junior group leader in September 2010. In September 2017, he was promoted to full group leader at HI-STEM and also became tenured head of the Division of Experimental Hematology at the DKFZ. The Experimental Hematology group is broadly interested in understanding fundamental biological properties of adult stem cells and applying this knowledge to gain new insight into human diseases and in the development of novel therapeutic strategies that may eventually be translated into the clinic to treat such diseases. Source: www.emedevents.com